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Summary

Background The association between cortisol secretion and mortality in patients with adrenal incidentalomas is
controversial. We aimed to assess all-cause mortality, prevalence of comorbidities, and occurrence of cardiovascular
events in uniformly stratified patients with adrenal incidentalomas and cortisol autonomy (defined as nonsuppressible serum cortisol on dexamethasone suppression testing).
Methods We conducted an international, retrospective, cohort study (NAPACA Outcome) at 30 centres in 16 countries.
Eligible patients were aged 18 years or older with an adrenal incidentaloma (diameter ≥1 cm) detected between
Jan 1, 1996, and Dec 31, 2015, and availability of a 1 mg dexamethasone suppression test result from the time of the
initial diagnosis. Patients with clinically apparent hormone excess, active malignancy, or follow-up of less than
36 months were excluded. Patients were stratified according to the 0800–0900 h serum cortisol values after an
overnight 1 mg dexamethasone suppression test; less than 50 nmol/L was classed as non-functioning adenoma,
50–138 nmol/L as possible autonomous cortisol secretion, and greater than 138 nmol/L as autonomous cortisol
secretion. The primary endpoint was all-cause mortality. Secondary endpoints were the prevalence of cardiometabolic
comorbidities, cardiovascular events, and cause-specific mortality. The primary and secondary endpoints were
assessed in all study participants.
Findings Of 4374 potentially eligible patients, 3656 (2089 [57·1%] with non-functioning adenoma, 1320 [36·1%]
with possible autonomous cortisol secretion, and 247 [6·8%] with autonomous cortisol secretion) were included in
the study cohort for mortality analysis (2350 [64·3%] women and 1306 [35·7%] men; median age 61 years
[IQR 53–68]; median follow-up 7·0 years [IQR 4·7–10·2]). During follow-up, 352 (9·6%) patients died. All-cause
mortality (adjusted for age, sex, comorbidities, and previous cardiovascular events) was significantly increased in
patients with possible autonomous cortisol secretion (HR 1·52, 95% CI 1·19–1·94) and autonomous cortisol
secretion (1·77, 1·20–2·62) compared with patients with non-functioning adenoma. In women younger than
65 years, autonomous cortisol secretion was associated with higher all-cause mortality than non-functioning
adenoma (HR 4·39, 95% CI 1·93–9·96), although this was not observed in men. Cardiometabolic comorbidities
were significantly less frequent with non-functioning adenoma than with possible autonomous cortisol secretion
and autonomous cortisol secretion (hypertension occurred in 1186 [58·6%] of 2024 patients with non-functioning
adenoma, 944 [74·0%] of 1275 with possible autonomous cortisol secretion, and 179 [75·2%] of 238 with
autonomous cortisol secretion; dyslipidaemia occurred in 724 [36·2%] of 1999 patients, 547 [43·8%] of 1250, and
123 [51·9%] of 237; and any diabetes occurred in 365 [18·2%] of 2002, 288 [23·0%] of 1250, and 62 [26·7%] of 232;
all p values <0·001).
Interpretation Cortisol autonomy is associated with increased all-cause mortality, particularly in women younger than
65 years. However, until results from randomised interventional trials are available, a conservative therapeutic
approach seems to be justified in most patients with adrenal incidentaloma.
Funding Deutsche Forschungsgemeinschaft, Associazione Italiana per la Ricerca sul Cancro, Università di Torino.
Copyright © 2022 Elsevier Ltd. All rights reserved.
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Research in context
Evidence before this study
Adrenal incidentalomas are found in at least 3% of adults.
In up to 50% of these people, endocrine investigations identify
evidence of biochemical hypercortisolism without clinically
overt glucocorticoid excess, a condition historically described
as subclinical Cushing’s syndrome. During preparation of the
European Society of Endocrinology and European Network for
the Study of Adrenal Tumours (ENSAT) 2016 Clinical
Guidelines on Management of Adrenal Incidentalomas,
a comprehensive literature search of PubMed, the NHS
Economic Evaluation Database, and the Cochrane Database of
Systematic Reviews and Database of Abstracts of Reviews of
Effects was performed, from Jan 1, 2000, to Nov 30, 2014,
for all systematic reviews and studies that had assessed any
association between cortisol autonomy (defined as
non-suppressible serum cortisol on dexamethasone
suppression testing) with morbidity and mortality. This search
revealed only two small studies, that together summarised
404 patients (including only 39 deaths), showing an increased
mortality in patients with unsuppressed cortisol after
dexamethasone. To confirm or refute this association, we
initiated the present study under the auspices of ENSAT. Due
to the paucity of available multicentre data for a sound power
calculation, we aimed initially to collect data from at least
2000 patients. In 2021, we updated our initial literature search
(to include literature from Dec 1, 2014, to July 31, 2021),
and identified a systematic review from 2020 and a Swedish
cohort study published in 2021. The systematic review, which
included 1356 patients from nine studies, could not confirm
the claimed association between cortisol autonomy and
mortality, whereas the more recent cohort study, which
included 1048 patients, found increased mortality in patients
in whom serum cortisol was greater than 83 nmol/L after
dexamethasone suppression testing.

Introduction
Over the past several decades, wider availability and use
of cross-sectional imaging has resulted in an increased
incidental detection of clinically inapparent adrenal
masses. Such adrenal incidentalomas have an increasing
age-dependent prevalence, ranging from 3% in adults
aged 50 years to 10% in adults older than 70 years.1–3
Most of these tumours are benign non-functioning
adrenal adenomas.3,4 However, endocrine investigations
find biochemical evidence of hypercortisolism in
30–50% of patients without clinically overt gluco
corticoid excess, which has historically been described
as subclinical Cushing’s syndrome. As only very few of
these patients progress to having overt Cushing’s
syndrome,5,6 it is currently recommended that patients
be categorised by the 0800–0900 h serum cortisol value
after an overnight 1 mg dexamethasone suppression
test; non-functioning adenoma was defined as less than
50 nmol/L, possible autonomous cortisol secretion as

Added value of this study
Our large, retrospective, international, cohort study, which
included more than 3600 patients with adrenal adenomas and
a follow-up of at least 3 years (median 7 years), provides
additional strong evidence for an overall association of possible
autonomous cortisol secretion (defined as 0800–0900 h serum
cortisol of 50–138 nmol/L after an overnight 1 mg
dexamethasone suppression test) and autonomous cortisol
secretion (defined as >138 nmol/L) with all-cause mortality.
To our knowledge, this is the first study to indicate that this risk
varies by age and sex. Women younger than 65 years with
autonomous cortisol secretion had the highest relative risk of
death, with an adjusted hazard ratio (HR) of 4·39 (95% CI
1·93–9·96), whereas men older than 65 years did not appear to
be at increased risk (HR 1·09, 95% CI 0·55–2·16) compared with
patients with non-functioning adenoma. We also confirmed
that the prevalence of cardiometabolic morbidity increases
progressively with the degree of cortisol autonomy, which was
more frequently detected in women and in the presence of
bilateral tumours.
Implications of all the available evidence
Although our study confirms the association between cortisol
autonomy, all-cause mortality and cardiometabolic morbidity,
we highlight a need for caution with regard to therapeutic
interventions. Our findings suggest that women younger than
65 years could benefit most from normalising cortisol secretion.
However, only randomised interventional trials will be able to
determine whether any intervention (either medical or surgical) is
able to mitigate both cardiometabolic morbidity and mortality in
patients with adrenal adenomas. Our study clearly provides the
rationale and the statistical basis for such a randomised trial.
Until these data are available, however, a conservative approach
seems reasonable, especially in men aged 65 years or older.

50–138 nmol/L, and autonomous cortisol secretion as
greater than 138 nmol/L.7
In 2019, a cohort study reported a slightly increased
mortality in 969 patients with adrenal incidentalomas
compared with 2907 patients without adrenal incident
alomas, as outlined by a multivariable-adjusted hazard
ratio (HR) for mortality of 1·14 (95% CI 1·00–1·29).8
Furthermore, several studies have focused on
the association between adrenocorticotropic hormone
(ACTH)-independent cortisol autonomy (defined as
non-suppressible serum cortisol on dexamethasone
suppression testing) and mortality in these patients, but
the results are conflicting. Three single-centre studies
that included 198–365 patients9–11 and one populationbased study from Sweden (that included 1048 patients)12
reported an increased mortality in people who had
elevated cortisol after the 1 mg dexamethasone
suppression test. By contrast, a systematic review
(including 32 studies and 4121 patients) found
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cardiovascular and metabolic risk factors (ie, hyper
tension, any diabetes, dyslipidaemia, and obesity) to be
more prevalent in the presence of what the authors
termed mild autonomous cortisol excess.6 However,
mortality was only studied in a subgroup of 1356 patients
from nine studies and was similar to that in patients with
non-functioning adrenal adenomas. In line with this
finding, a population-based study from Minnesota, USA,
compared 1004 patients with adrenal incidentalomas to
sex-matched and age-matched participants without
adrenal tumours and found no difference in mortality.13
These discrepancies might be explained in part by the
heterogeneity of the criteria used for the definition of
cortisol autonomy in these studies.
Taken together, although it is plausible that there is
an association between low-grade cortisol excess
(as shown by dexamethasone suppression test), comor
bidities (including cardiovascular events), and mortality,
previously studies were limited by small sample sizes
and potential single-centre bias. We aimed to assess
all-cause mortality, prevalence of comorbidities, and
occurrence of cardiovascular events in patients with
adrenal incidentalomas, applying unified diagnostic
criteria to define cortisol autonomy.

Methods

Study design
We conducted an international, retrospective, cohort
study at 30 centres in 16 countries (NAPACA Outcome).
The study was approved by the European Network
for the Study of Adrenal Tumours (ENSAT) in
December, 2014. Each centre had local ethical approval
for pseudonymised, standardised, phenotype recording.
All patients provided written informed consent to
participate (except for at nine centres where the ethics
committees waived this requirement). Centres were
asked to report patients in a consecutive manner to
minimise selection bias. Retrospective data acquisition
was done over a 56-month period (from January, 2015,
to August, 2019).

Participants
Patients were eligible for inclusion if they were aged
18 years or older and had an adrenal incidentaloma
(unilateral or bilateral with a diameter ≥1 cm) detected
by cross-sectional imaging between Jan 1, 1996, and
Dec 31, 2015, diagnosis of an adrenal adenoma based on
typical imaging characteristics7 or follow-up imaging
excluding malignancy, availability of a 1 mg dexa
methasone suppression test result from the time of the
initial diagnosis, and follow-up data on survival status
and occurrence of cardiovascular events with a follow-up
duration of at least 36 months. Exclusion criteria were a
confirmed diagnosis of clinically overt Cushing’s
syndrome (defined according to an established clinical
practice guideline14 as presence of hypercortisolism with
specific clinical signs of cortisol excess, such as easy

bruising, facial plethora, and proximal myopathy),
ACTH-dependent hypercortisolism, urinary free cortisol
greater than or equal to two times the upper limit of
normal, phaeochromocytoma, primary aldosteronism,
surgery within 36 months after initial diagnosis, or any
active malignancy (including adrenocortical carcinoma)
at the time of primary diagnosis of the adrenal mass. The
considerable variation in use of other diagnostic tests at
different centres, including plasma ACTH and urinary
free cortisol, precluded formal analysis of other tests.

Procedures
Following the European Society of Endocrinology and
ENSAT 2016 Clinical Guidelines on Management of
Adrenal Incidentalomas,7 patients were categorised
according to their first 0800–0900 h serum cortisol result
on an overnight 1 mg dexamethasone suppression test
after initial diagnosis of the adrenal incidentaloma; less
than 50 nmol/L was classed as non-functioning adenoma,
50–138 nmol/L as possible autonomous cortisol secretion,
and greater than 138 nmol/L as autonomous cortisol
secretion. The conversion factor for serum cortisol in
µg/dL is nmol/L divided by 27·59 (hence, important
cutoffs for the 1 mg dexamethasone suppression test are
50 nmol/L or 1·8 µg/dL, and 138 nmol/L or 5·0 µg/dL).
We collected data on age, sex, and BMI from the time of
the initial diagnosis of adrenal incidentaloma; tumour
characteristics (ie, size and laterality); and medical history
(eg, cardiometabolic risk factors and cardiovascular
events) both at primary diagnosis and during follow-up.
Diagnosis of comorbidities was done according to the
existing guidelines available at the time of adrenal tumour
diagnosis.

Outcomes
The primary endpoint was all-cause mortality. Prespecified
secondary endpoints were prevalence of cardiometa
bolic comorbidities (hypertension, any diabetes, and
dyslipidaemia), occurrence of cardiovascular events, and
cause-specific mortality. The primary and secondary
endpoints were assessed in all study participants.
For cardiovascular morbidity, we defined a composite
endpoint of the following major adverse cardiovascular
events (MACE): myocardial infarction or coronary
revascularisation (either bypass surgery or percutaneous
intervention), stroke, or cardiovascular-related death. In
addition, we collected data on venous thrombosis and
pulmonary embolism.

Statistical analysis
Patients who had surgery after at least 36 months of followup were censored, setting the date of surgery as the date of
last follow-up. For subgroup analyses, patients were
categorised according to their age at diagnosis (<65 years vs
≥65 years, based on age-dependent thresholds established
to assess cardiovascular risk in patients with diabetes or
hypertension15,16), with separate analyses by sex.
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Absolute numbers and percentages were calculated for
categorical data. Missing values were discounted when
calculating proportions. The results for continuous
variables are expressed as medians with IQR. The
intergroup differences between the different dexa
methasone suppression test categories were analysed via
χ² test. All-cause mortality was calculated as the time
between the initial diagnosis of the adrenal incidentaloma
and death or last follow-up.
A power analysis was performed on the basis of the
assumption of a clinically meaningful HR of at least 1·5
for a two-group comparison and a mortality rate of
about 10%. Using a type I error α of 0·05 and
a power of 80%, about 2000 patients with 191 deaths would
need to be included. Survival curves were constructed
using the Kaplan-Meier method, and the log-rank test was
used for subgroup analysis. Patients were censored either
at the date of last follow-up, adrenalectomy, or death.
Relevant prognostic variables were identified by univariable
and multivariable analyses, using the Cox proportional
hazards model. HRs are provided with 95% CIs. Multi
variable Cox analyses included the three dexamethasone
suppression test categories (non-functioning adenoma,
possible autonomous cortisol secretion, and autonomous
cortisol secretion) and known prognostic factors for

all-cause mortality and cardiovascular events (age, sex, any
diabetes, hypertension, dyslipidaemia, and any previous
cardiovascular event) as covariables. To study the functional
forms of a relationship between cortisol after the 1 mg
dexamethasone suppression test as a continuous variable
and all-cause mortality, we applied restricted cubic splines.
For the subgroup analyses by age and sex, we used
a formal three-way interaction test, using Cox regression
for age (<65 years or ≥65 years), sex (male or female),
and dexamethasone suppression test category (nonfunctioning adenoma, possible autonomous cortisol
secretion, or autonomous cortisol secretion). Time to
first MACE was defined as the time between the initial
diagnosis of the adrenal incidentaloma and first
documentation of any MACE thereafter. As a quality check
for data integrity, a completeness index was calculated for
each centre: patients with available follow-up data within
the previous 12 months on Dec 31, 2018 were counted as
complete (ie, centres with an index of ≥90% qualified for
a subgroup analysis), and the results were then compared
with those derived from the whole study group. Two-tailed
p values of less than 0·05 were deemed significant.
Following the cutoff criteria of a study published in
2021,12 we performed a post-hoc analysis where we
divided our study cohort into four groups on the basis of

All patients
(n=3656)

Non-functioning
Possible
adenoma (n=2089) autonomous
cortisol secretion
(n=1320)

Autonomous
cortisol secretion
(n=247)

Women

2350 (64·3%)

1321 (63·2%)

860 (65·2%)

169 (68·4%)

Men

1306 (35·7%)

768 (36·8%)

460 (34·8%)

78 (31·6%)

61 (53–68)

60 (52–67)

63 (56–70)

63 (55–70)

2264 (61·9%)

1404 (67·2%)

726 (55·0%)

134 (54·3%)

Sex

Age, years
Age <65 years
Follow-up, years
BMI, kg/m²*

7·0 (4·7–10·2)

7·2 (4·8–10·5)

6·9 (4·7–10·0)

6·9 (4·5–10·0)

28·1 (25·0–32·3)

28·6 (25·4–32·6)

27·8 (24·6–31·9)

27·7 (24·3–31·9)

Tumour characteristics†
Left side

1497 (44·6%)

946 (49·8%)

468 (38·1%)

83 (36·2%)

Right side

1093 (32·6%)

646 (34·0%)

385 (31·4%)

62 (27·1%)

764 (22·8%)

306 (16·1%)

374 (30·5%)

84 (36·7%)

22 (15–30)

20 (15–25)

26 (19–33)

29 (20–37)

47 (30–72)

33 (28–50)

72 (61–94)

190 (157–253)

Bilateral
Maximum tumour diameter, mm
1 mg dexamethasone suppression test serum cortisol result, nmol/L
Comorbidities
Hypertension‡

2309 (65·3%)

1186 (58·6%)

944 (74·0%)

179 (75·2%)

Dyslipidaemia§

1394 (40·0%)

724 (36·2%)

547 (43·8%)

123 (51·9%)

Any diabetes¶

715 (20·5%)

365 (18·2%)

288 (23·0%)

62 (26·7%)

Previous cardiovascular events
199 (6·0%)

87 (4·6%)

96 (8·0%)

16 (7·1%)

Stroke**

Myocardial infarction or coronary intervention, or both||

70 (2·1%)

31 (1·6%)

27 (2·3%)

12 (5·3%)

Deep vein thrombosis or pulmonary embolism, or both††

62 (1·9%)

31 (1·7%)

26 (2·2%)

5 (2·2%)

319 (9·3%)

150 (7·6%)

139 (11·4%)

30 (13·2%)

At least one cardiovascular event‡‡

Data are n (%) or median (IQR). Centre-specific data on ethnicity are shown in the appendix (p 2). *n=3216. †n=3354. ‡n=3537. §n=3486. ¶n=3484. ||n=3306. **n=3299.
††n=3293. ‡‡n=3415.

Table 1: Patient characteristics at initial diagnosis of the adrenal incidentaloma

4

www.thelancet.com/diabetes-endocrinology Published online May 6, 2022 https://doi.org/10.1016/S2213-8587(22)00100-0
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on June 23, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

Articles

Role of the funding source
The funders of the study had no role in study design,
data collection, data analysis, data interpretation, or
writing of the report.

A
100
80
Overall survival (%)

dexamethasone suppression test result (ie, serum
cortisol <50 nmol/L, 50–80 nmol/L, 81–138 nmol/L, and
>138 nmol/L).
Statistical analyses were performed using SPSS
(version 28.0), and R (version 4.0.2) using the survival
(version 3.2-13) and smoothHR (version 1.0.3) packages.

40
Non-functioning adenoma (n=2089)
Possible autonomous cortisol secretion (n=1320)
Autonomous cortisol secretion (n=247)

20

Results

0

0

Number at risk
(number censored)
Non-functioning adenoma 2089 (0)
Possible autonomous cortisol secretion 1320 (0)
Autonomous cortisol secretion
247 (0)

60

120

180

1504 (539) 579 (1400) 123 (1833)
932 (340) 325 (862)
74 (1085)
168 (66)
63 (154)
13 (197)

240

300

14 (1935)
11 (1143)
1 (205)

0 (1946)
0 (1152)
0 (206)

B
100
90
Overall survival (%)

Of 4374 potentially eligible patients, 3656 from 28 centres
in 15 countries were included in the study cohort for
mortality analysis (appendix pp 2, 8). In 131 (3·6%) patients,
adrenalectomy was performed later than 36 months after
initial diagnosis (appendix p 3); these patients were
censored at the time of surgery. Median age at initial
diagnosis was 61 years (IQR 53–68), and 2350 (64·3%)
patients were women and 1306 (35·7%) were men.
According to the result of the first dexa
methasone
suppression test, 2089 (57·1%) of 3656 patients had nonfunctioning adenoma, 1320 (36·1%) had possible
autonomous cortisol secretion, and 247 (6·8%) had
autonomous cortisol secretion. Bilateral tumours were
most frequent in patients with autonomous cortisol
secretion, and this group also had the largest median
tumour diameter (table 1). Serum cortisol after the 1 mg
dexamethasone suppression test increased with age
(appendix p 9). None of the patients developed overt
Cushing’s syndrome during follow-up.
During a median follow-up of 7·0 years (IQR 4·7–10·2),
352 (9·6%) of 3656 patients died. Figure 1A shows the
crude overall survival of the three dexamethasone
suppression test groups. Compared with patients with
non-functioning adenoma, the proportion of patients
who died was higher in those with possible autonomous
cortisol secretion and autonomous cortisol secretion
(143 [6·8%] of 2089 patients vs 168 [12·7%] of 1320 and
41 [16·6%] of 247, respectively). After multivariable Cox
analysis adjusting for age, sex, hypertension, any diabetes,
dyslipidaemia, and previous cardiovascular events, allcause mortality was significantly higher in patients with
possible autonomous cortisol secretion (HR 1·52, 95% CI
1·19–1·94; p=0·001) and autonomous cortisol secretion
(1·77, 1·20–2·62; p=0·004) than in patients with nonfunctioning adenoma (figure 1B). Bilateral adenomas had
a greater association with possible autonomous cortisol
secretion and autonomous cortisol secretion (table 1), but
presence of bilateral adenomas was itself not an
independent risk factor for death (data not shown).
Information on the individual causes of death was
available in 306 (86·9%) of 352 patients who died
(figure 2). The two most frequent causes of death were
cancer (98 patients) and cardiovascular-related events
(95 patients; appendix p 6).

60

80
70
Non-functioning adenoma (n=1948)
Possible autonomous cortisol secretion (n=1205)
Autonomous cortisol secretion (n=226)
Possible autonomous cortisol secretion
HR 1·52 (95% CI 1·19–1·94); p=0·001
Autonomous cortisol secretion
HR 1·77 (95% CI 1·20–2·62); p=0·004

60
50
40
0

0

60

120

180

240

Duration of follow-up (months)

Figure 1: Overall survival in the entire cohort
(A) Kaplan-Meier curves (n=3656); ticks indicate censored patients; median overall survival was not reached in the
non-functioning adenoma group, 246 months in the possible autonomous cortisol secretion group, and 206
months (95% CI 187–209) in the autonomous cortisol secretion group; overall log-rank p<0·001 (non-functioning
adenoma group vs possible autonomous cortisol secretion group, p<0·001; non-functioning adenoma group vs
autonomous cortisol secretion group, p<0·001; possible autonomous cortisol secretion group vs autonomous
cortisol secretion group, p=0·10). (B) Multivariable Cox regression analysis (n=3379; adjusted for sex, age,
hypertension, dyslipidaemia, any diabetes, and previous cardiovascular events); patients with missing data for
these variables were excluded from the analysis. HR=hazard ratio.

In the post-hoc analysis when we divided the study
cohort into four groups, we found that all-cause mortality
in the 766 patients with a serum cortisol of 50–80 nmol/L
was not significantly higher than in the less than
50 nmol/L non-functioning adenoma group (HR 1·29,
95% CI 0·97–1·71; p=0·085; appendix p 4). Furthermore,
when we studied serum cortisol after the dexamethasone
suppression test as a continuous variable in relation to
all-cause mortality, although there was no significant
linear relationship in the entire cohort, we found a linear
increase in the HR for death in patients with serum
cortisol of 138 nmol/L or less (appendix p 10).
In sensitivity analyses, 10-year overall survival was
heterogeneous among centres (ranging from 69% to
100%). In the analysis restricted to the 21 centres with
more reliable follow-up (completeness index score ≥90%),

See Online for appendix
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overall survival of the 2730 patients was not changed in
a relevant manner compared with the entire study cohort
(appendix p 5). Accordingly, we decided not to exclude
any centre from the analysis. The association between
mortality and the degree of cortisol autonomy was agedependent; in patients younger than 65 years, all-cause
mortality was significantly higher in the autonomous
cortisol secretion group than in the non-functioning
adenoma group (adjusted HR 3·16, 95% CI 1·65–6·05),
whereas there was no significant difference in patients
aged 65 years or older (1·43, 0·87–2·33). The association
between mortality and serum cortisol after the
dexamethasone suppression test was much stronger in
women than in men (autonomous cortisol secretion vs
non-functioning adenoma; adjusted HR 2·50 [95% CI
1·45–4·31] in women vs 1·19 [0·67–2·10] in men). The
combined analysis of age-specific and sex-specific
mortality is presented in table 2 and figure 3. This
analysis revealed a significant interaction of age, sex, and
dexamethasone suppression test category (p<0·01). It is
important to note, however, that the number of patients
in each of these groups meant that a separate formal
analysis group by group was underpowered.
Data on cardiometabolic morbidity and cardiovascular
events were available in 3484 (95·3%) of 3656 patients
(2002 with non-functioning adenoma, 1250 with possible
autonomous cortisol secretion, and 232 with autonomous
cortisol secretion). Overall, hypertension was the most

Proportion of patients who died (%)

40
20
20

Non-functioning adenoma
Possible autonomous cortisol secretion
Autonomous cortisol secretion

15
10
5
0

Cardiovascular

Cancer

Infection

Other
causes

Unknown All causes

Figure 2: Mortality and causes of death
Error bars are 95% CI.

Women
Men

All
events, n

frequent comorbidity at initial diagnosis (2309 [65·3%] of
3537 patients), followed by dyslipidaemia (1394 [40·0%]
of 3486), and any diabetes (715 [20·5%] of 3484). The
prevalence of each of these comorbid conditions by group
increased sequentially from lowest in the non-functioning
adenoma group to highest in the autonomous cortisol
secretion group (table 1).
With regard to cardiovascular endpoints, 319 (9·3%) of
3415 patients had experienced at least one cardiovascular
event by the time of the initial diagnosis of the adrenal
incidentaloma (table 1). During follow-up, a total of
476 non-fatal cardiovascular events occurred in 375 patients,
with more cardiovascular events occurring in patients with
possible autonomous cortisol secretion and autonomous
cortisol secretion than in patients with non-functioning
adenoma. Overall, 297 (8·9%) of 3325 patients with
available data experienced a MACE (145 [7·3%] patients
in the non-functioning adenoma group, 130 [10·3%] in
the possible autonomous cortisol secretion group, and
22 [9·4%] in the autonomous cortisol secretion group;
appendix p 7). However, after adjusting for cardiometa
bolic comorbidities, compared with patients with nonfunctioning adenoma, time to the first MACE was only
significantly shorter in women aged 65 years or older with
autonomous cortisol secretion (table 3).

Discussion
To our knowledge, this study is the largest retrospective
analysis on mortality and cardiovascular morbidity in
patients with adrenal incidentalomas performed to date.
By contrast with a meta-analysis from 2019,6 but similar
to a study from Sweden published in 2021,12 we found
that all-cause mortality was increased in patients with
possible autonomous cortisol secretion and autonomous
cortisol secretion compared with patients with nonfunctioning adenoma. Because of our large sample size
(>3600 patients), we were able to reliably analyse effects
of age and sex on mortality. Our findings show that,
compared with patients with non-functioning adenoma,
autonomous cortisol secretion in women younger than
65 years was associated with a four-times increase in
adjusted all-cause mortality, whereas all-cause mortality
in the autonomous cortisol secretion group was only
moderately increased in women aged 65 years or older

Age,
years

All
patients, n

Possible autonomous cortisol secretion

Autonomous cortisol secretion

Patients, n

HR

95% CI

p value

Patients, n

HR

95% CI

p value

<65

1424

51

472

1·82

0·99–3·31

0·052

96

4·39

1·93–9·96

<0·001

≥65

723

108

302

1·99

1·31–3·01

0·001

57

1·80

0·86–3·76

0·12

<65

734

43

222

1·35

0·70–2·59

0·37

34

1·77

0·59–5·33

0·31

≥65

479

94

200

1·26

0·81–1·97

0·31

36

1·09

0·55–2·16

0·81

The analysis was adjusted for hypertension, any diabetes, dyslipidaemia, and previous cardiovascular events. Patients with missing data for these variables were excluded
from the analysis. Patients with non-functioning adenoma were the reference cohort. HR=hazard ratio.

Table 2: Multivariable Cox regression analysis of all-cause mortality by sex and age

6

www.thelancet.com/diabetes-endocrinology Published online May 6, 2022 https://doi.org/10.1016/S2213-8587(22)00100-0
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on June 23, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

Articles

Women aged <65 years

Men aged <65 years

Non-functioning adenoma (n=856)
Possible autonomous cortisol secretion
(n=472)
Autonomous cortisol secretion (n=96)
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Possible autonomous cortisol secretion
(n=222)
Autonomous cortisol secretion (n=34)

100

100
90

Overall survival (%)
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40
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0

60

Men aged ≥65 years

Women aged ≥65 years

Overall survival (%)

and men younger than 65 years, and was not affected in
men aged 65 years or older.
We found that possible autonomous cortisol secretion
and autonomous cortisol secretion were associated with
an increased frequency of cardiometabolic comorbidities.
In particular, hypertension had a higher prevalence in
both the possible autonomous cortisol secretion and
autonomous cortisol secretion groups than in the nonfunctioning adenoma group, and any diabetes and
dyslipidaemia showed progressively increased frequencies
in the non-functioning adenoma, possible autonomous
cortisol secretion, and autonomous cortisol secretion
groups, reflecting a continuum in metabolic disturbance,
as shown previously.17,18 Further
more, cardiovascular
events occurring either before or after the initial diagnosis
of the adrenal tumour were more frequently observed in
patients with possible autonomous cortisol secretion and
autonomous cortisol secretion than in patients with nonfunctioning adenoma. However, after adjusting for
cardiometabolic comorbidities, a significant increase in
MACE was only observed in women aged 65 years or older
with autonomous cortisol secretion, suggesting that
glucocorticoid-related cardiovascular events might not be
the main drivers of overall mortality in this cohort, as has
been suggested previously.9,10,12 This finding is in line with
the reported causes of death, which indicated there were
few cardiovascular-related deaths in women younger than
65 years with cortisol autonomy. In our study, we found a
relative increase in cardiovascular-related mortality, which
paralleled that for other causes of death in patients with
autonomous cortisol secretion. Another study pointed to
cancer as the leading cause of death in the presence of
autonomous cortisol secretion;11 we could only partly
confirm this observation in our large cohort in which
cardiovascular-related and cancer-related deaths were
almost equal in patients with cortisol autonomy (appendix
p 6). In line with other studies, however, our findings
suggest that cortisol autonomy might have systemic
detrimental effects.18–20 Nevertheless, we are aware that
a retrospective study can by definition never confirm any
causal relationship.
The finding that the association between autonomous
cortisol secretion and mortality appeared to be clinically
relevant mostly in younger women has not yet been
described by other studies and might suggest that auto
nomous cortisol secretion is a prognostic factor that has
greater influence at younger ages, when other age-related
comorbidities are less prominent. Although a different
clinical presentation was observed for men and women
with overt Cushing’s disease,21 less is known about sexspecific organ effects by hypercortisolism. Studies on
stress associated with the COVID-19 pandemic have
shown that younger and middle-aged women were more
susceptible to stress than men, and displayed an increased
vascular reactivity to glucocorticoids.22 Besides, it has been
shown that women with any diabetes or coronary heart
disease were likely to receive less aggressive medical

0

60

120

180

Duration of follow-up (months)

Possible autonomous
cortisol secretion HR 1·26
(95% CI 0·81–1·97; p=0·31)
Autonomous cortisol secretion
HR 1·09 (95% CI 0·55–2·16); p=0·81

40
20

240
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Figure 3: Overall survival by sex and age
Multivariable Cox regression analysis adjusted for hypertension, dyslipidaemia, any diabetes, and previous
cardiovascular events. Patients with missing data for these variables were excluded from the analysis.
HR=hazard ratio.

management of their cardiovascular risk factors, which
might have contributed to sex differences in cardiovascular
mortality.23,24 In the present study, however, we adjusted
our survival analysis for comorbidities to mitigate the risk
of such a confounder. Interestingly, a large, prospective,
multicentre study in 1305 patients with adrenal adenomas
showed an increased risk and severity of hypertension and
type 2 diabetes in patients with cortisol autonomy and,
similar to our findings, showed an increasing proportion
of affected women with increasing cortisol after a 1 mg
dexamethasone suppression test.25 Although it would be
important to screen for (and treat) autonomous cortisol
secretion in young (and presumably otherwise more
healthy) patients, it is probably less relevant to do so in
frail older patients. However, only a large, randomised,
intervention trial would provide a definitive answer, and
such a trial is not yet available. Thus, for the time being,
our study suggests that any decision on initiating cortisollowering treatment or surgery should be made with care,
and on an individual basis.
We also observed that serum cortisol after the
dexamethasone suppression test increased with age.
A retrospective study, however, cannot establish whether
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Age,
years

Women
Men

All
patients, n

All
events, n

Possible autonomous cortisol secretion

Autonomous cortisol secretion

Patients, n

HR

95% CI

p value

Patients, n

HR

95% CI

p value

<65

1377

75

466

1·20

0·74–1·95

0·46

94

1·61

0·71–3·61

0·25

≥65

705

92

296

1·33

0·84–2·06

0·22

56

2·09

1·08–4·05

0·028

<65

694

91

218

1·05

0·67–1·63

0·83

33

0·73

0·29–1·85

0·51

≥65

466

89

193

1·10

0·70–1·72

0·69

36

1·04

0·48–2·24

0·92

The analysis was adjusted for hypertension, any diabetes, dyslipidaemia, and previous cardiovascular events. Patients with missing data for these variables were excluded
from the analysis. Patients with non-functioning adenoma were the reference cohort. HR=hazard ratio. MACE=major adverse cardiovascular event.

Table 3: Multivariate Cox regression analysis of MACE by sex and age

this association might also reflect chronic stress
associated with age-related illnesses. Future studies will
have to confirm this finding and clarify if this is
a hallmark of the brain aging process affecting the
hypothalamic–pituitary–adrenal axis,26 reduced cortisol
inactivation due to a reduced activity of 11b-hydroxysteroid
dehydrogenase type 2 as a consequence of a lower
nephron mass in ageing,27 increasing adrenal tumour
mass with age,18 or potentially accelerated metabolism
of dexamethasone (eg, CYP3A4 induction due to
polypharmacy in older patients).28 Overall, these data
raise questions as to the clinical importance of elevated
serum cortisol after the 1 mg dexamethasone suppression
test in older patients. Besides, as has been reported
previously,12 we could not find any clear relationship
between cortisol after the dexamethasone suppression
test as a continuous variable and all-cause mortality in
the entire cohort. However, there was a nearly linear
relationship when serum cortisol was 138 nmol/L or less.
For higher values, the accuracy of the results was likely to
be limited by the low number of patients.
This study has several limitations. First, a retrospective
design is prone to bias, including heterogeneous or
possibly inaccurate capture of relevant clinical infor
mation. Nevertheless, we tried to minimise such an
impact by requesting consecutively recruited patients,
a minimum number of included patients per centre,
and did a sensitivity analysis focusing on centres with
a follow-up rate of more than 90%. Second, the number
of patients with the highest serum cortisol after the 1
mg dexamethasone suppression test (ie, the autonomous
cortisol secretion group) was small compared with the
number in the possible autonomous cortisol secretion
and non-functioning adenoma groups, which might
have weakened the statistical power of some of our
analyses. However, the 247 patients in the autonomous
cortisol secretion group exceeded the total number of
patients included in all previous studies on this topic
(n=154).9–12 Third, we relied on a single 1 mg
dexamethasone suppression test only, with variability in
the performance of the cortisol assays used between
centres over time, and without availability of
dexamethasone serum concentrations.29 However, the
biochemical tests used to assess for cortisol autonomy
8

have not been changed over the last 25 years. Fourth, it
is possible that the inclusion criterion of a 1 mg
dexamethasone suppression test result in itself leads to
some bias, because some patients with adrenal
incidentaloma might not have undergone testing.
However, this bias is not resolvable, as shown by
a population-based study in which only few patients
with adrenal incidentalomas had some type of endocrine
screening.13 In addition, we acknowledge that all partici
pating institutions are tertiary care centres and our
sample might not be representative of patients seen in
the community. Finally, the diagnostic criteria of the
comorbidities were not uniform across centres and have
changed over the study period of 23 years.
In conclusion, this large, retrospective, international,
cohort study provides additional strong evidence for an
overall association between possible autonomous
cortisol secretion and autonomous cortisol secretion
and increased all-cause mortality (although causality
cannot be confirmed due to the retrospective study
design). However, this risk was not equally distributed.
Women younger than 65 years with autonomous
cortisol secretion had the highest relative risk, whereas
men aged 65 years or older did not appear to be at
increased risk (irrespective of the degree of cortisol
autonomy). Although several studies have claimed
benefits of adrenalectomy in patients with autonomous
cortisol secretion, all of these studies were prone to bias
and had small sample sizes.30 Randomised interventional
trials are needed to determine whether intervention
(either medical or surgical) is able to mitigate the
cardiometabolic morbidity and mortality in patients
with adrenal adenomas. On the basis of our findings,
and until results from such trials are available, we
suggest that a conservative approach might be prudent,
in particular in men aged 65 years or older with cortisol
autonomy.
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